| Objectives：Vascular endothelial dysfunction is regarded as a marker forthe development and progression of atherosclerosis. It is now widelyrecognized that endothelial damage play a central role in the pathogenesis ofcardiovascular disease. With the the deterioration of endothelial dysfunction,arterial elasticity is reduced and atherosclerosis is occured and deteriorated.Rosuvastatin can improve endothelial function in patients with acute coronarysyndrome by reducing LDL-cholesterol and pleiotropic effects. B-groupvitamin supplementation restores endothelial function mainly by reducinghomocysteine-induced oxidative stress. In this study, we evaluated the effectsof rosuvastatin, B-group vitamins and their combination on endothelialfunction in patients with acute coronary syndrome.Methods：We selected60acute coronary syndrome patients who came tothe Second Hospital of Hebei Medical University from July2013to December2013. All selection objects conform to the diagnostic criteria for acutecoronary syndrome. They were randomly, double-blinded assigned to threegroups, including group B (n=30): treated with Rosuvastatin10mg andVitamin placebo for6weeks, group C (n=30): treated with vitaminsupplementation consisting of folic acid5mg, vitamin B120.5mg, B610mgand Rosuvastatin10mg for6weeks. There was no significant difference inage, sex, smoking, body mass index, blood pressure, blood sugar and bloodlipid among the three groups (P>0.05). In addition, the sex, age-matchedhealthy volunteers30cases as control group (A group), given vitamin placeboand rosuvastatin for6weeks.Hcy levels were determined by high pressureliquid fluorescence detection, OX-LDL levels were measured byenzyme-linked immunosorbent assay (ELISA), ET-1levels were measured by Radioimmunoassay,and NO levels were measured by nitrate reductase.Endothelial function was assessed by plasma NO and ET-1levels. The data istreated with statistics software SPSS13.0for windows. Statistical analysis wasperformed using one-way ANOVA, Paired T test,the linear regression andcorrelation. P-value＜0.05was considered to be significant.Results：1At baseline, NO, OX-LDL, ET-1and Hcy were no significantdifference among B and C group.(P＞0.05).The plasma OX-LDL, ET-1, Hcylevels between B group and C group were lower than those in group A, theplasma NO levels between B group and C group were higher than those ingroup A, the differences were statistically significant (P <0.05).2Analyze the NO level in A group,B group, C group: The NO levels inA group,B group, C group were72.27±6.30μmol/L、66.87±5.30μmol/L、72.19±4.38μmol/L; The NO levels in A and C group were significantlyhigher than those in B group（P＜0.01）. The NO levels were no significantdifference among A and C group (P＞0.05). The plasma NO levels aftertreatment were higher than those before treatment in B group and C group,the difference was statistically significant (P<0.01); The plasma NO levelsbefore and after treatment were not statistically significant in A group (P>0.05).3Analyze the Hcy level in A group,B group, C group: The Hcy levels inA group,B group, C group were9.94±2.57μmol/L、13.47±2.79μmol/L、11.2±2.46μmol/L；The Hcy levels in A and C group were significantly lowerthan those in B group（P＜0.01）. The Hcy levels were no significantdifference among A and C group (P＞0.05). The plasma Hcy levels aftertreatment were lower than those before treatment in B group and C group, thedifference was statistically significant (P<0.01); The plasma Hcy levels beforeand after treatment were not statistically significant in A group (P>0.05).4Analyze the OX-LDL level A group,B group, C group: The OX-LDLlevels in A group,B group, C group were40.56±2.55μg/L、51.36±1.96μg/L、41.69±2.05μg/L；The OX-LDL levels in A and C group were significantly lower than those in B group（P＜0.01）. The OX-LDL levels wereno significant difference among A and C group (P＞0.05). The plasmaOX-LDL levels after treatment were lower than those before treatment in Bgroup and C group, the difference was statistically significant (P<0.01); Theplasma OX-LDL levels before and after treatment were not statisticallysignificant in A group (P>0.05).5Analyze the ET-1level A group,B group, C group: The OX-LDLlevels in A group,B group, C group were57.04±6.51μmol/L、61.30±5.49μmol/L、57.93±6.18μmol/L；The ET-1levels in A and C group weresignificantly lower than those in B group（P＜0.01）. The ET-1levels were nosignificant difference among A and C group (P＞0.05). The plasma ET-1levels after treatment were lower than those before treatment in B group and Cgroup, the difference was statistically significant (P <0.01); The plasma ET-1levels before and after treatment were not statistically significant in A group(P>0.05).6The NO level was negatively correlated with OX-LDL level（r=-0.-0.529,P＜0.01),and the linear regression equation was:Y=95.162-0.551X. The Hcy level was positively correlated with OX-LDLlevel （r=0.517,P＜0.01),and the linear regression equation was:Y=34.693+0.958X. The ET-1level was positively correlated with OX-LDLlevel （r=0.403,P＜0.01）,and the linear regression equation was:Y=38.106+0.462X.The Hcy level was no correlated with the NO level. TheET-1Hcy level was no correlated with the NO level.Conclusions：Rosuvastatin and B-group vitamin supplementation improved endothelialfunction in ACS patients. The combination of both therapies had an additiveeffect on endothelial function. |
PDF Full Text Request